Corona Remedies IPO opens today: Should you subscribe to the ₹655 crore issue?

On valuations, the company is seeking a P/E of 35.3 times based on annualised FY26 earnings, with a post-issue market cap of about ₹6,495 crore, making the issue appear fairly priced.

Leave a Reply

Your email address will not be published. Required fields are marked *